SSGA Active Trust has released its latest NPORT-P filing, which provides crucial insights into the company's financial performance and investment strategies. This update is significant as it outlines the trust's assets and liabilities, reflecting its ongoing commitment to managing investments effectively in a competitive landscape.
As of August 31, 2026, SSGA Active Trust reported total assets of approximately $28.4 million, with liabilities amounting to about $1.5 million. This results in net assets of roughly $26.9 million. The filing underscores the trust's focus on corporate bonds, particularly through its State Street(R) My2031 Corporate Bond ETF, which is a key component of its investment strategy.
Background
SSGA Active Trust, identified by CIK 0001516212, operates as an investment entity. The trust is known for its active management of investment portfolios, particularly in the realm of corporate bonds. The recent filing is part of a series of NPORT-P submissions made on October 28, 2026, highlighting the trust's ongoing financial activities.
What the Filing Says
The NPORT-P filing, dated October 28, 2026, reveals that the trust's total assets are approximately $28,408,133.37, with total liabilities of $1,483,191.11. The net assets are reported at $26,924,942.26. Additionally, the filing notes various investment strategies and metrics related to interest rate risks and credit spreads.
Impact
This filing may impact investors and stakeholders in the investment management sector, particularly those focused on corporate bonds. The detailed breakdown of assets and liabilities offers insights that could influence investment decisions and strategies among competitors. Notably, the trust has engaged with several prominent borrowers, including BNP Paribas USA, BofA Securities, and HSBC Securities, which may reflect its robust investment approach.
What's Next
The filing does not specify what happens next for SSGA Active Trust, leaving stakeholders to anticipate further updates or filings in the future.
Read Next
van Houte Hans Reports Stock Transactions at Nurix Therapeutics
Hansen Gwenn Acquires and Sells Shares at Nurix Therapeutics
Drouillard Vincent Amends Filing to Correct Share Sale Details
Drouillard Vincent reports sale of 10,000 shares in AerCap
Gilead Sciences CEO Daniel O'Day Executes Multiple Stock Sales
Le Peuch Olivier Sells 25,000 Shares of SLB Limited





